Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Financing Activities: 2023-2024

Historic Cash from Financing Activities for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $71.7 million.

  • Inhibrx Biosciences' Cash from Financing Activities was N/A to $352,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $171.9 million, marking a year-over-year change of. This contributed to the annual value of $71.7 million for FY2024, which is 64.51% down from last year.
  • According to the latest figures from FY2024, Inhibrx Biosciences' Cash from Financing Activities is $71.7 million, which was down 64.51% from $202.0 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Cash from Financing Activities registered a high of $202.0 million during FY2023, and its lowest value of $71.7 million during FY2024.
  • For the 2-year period, Inhibrx Biosciences' Cash from Financing Activities averaged around $136.8 million, with its median value being $136.8 million (2023).
  • Data for Inhibrx Biosciences' Cash from Financing Activities shows a maximum YoY plummeted of 64.51% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Inhibrx Biosciences' Cash from Financing Activities stood at $202.0 million in 2023, then plummeted by 64.51% to $71.7 million in 2024.